Summary
Introduction
Cutaneous synthesis of cholecalciferol in response to U.V. irradiation is considered to be important in maintaining vitamin D status in man [l, 21. Little is known about the influence of environmental U.V. energy, or of the effect of age, anatomical site or drugs associated with derangement of vitamin D metabolism on the capacity of human skin to synthesize cholecalciferol in vivo. It is important to consider the skin response in vivo since isolated skin may respond differently [31. Acquisition of a skin biopsy after U.V. irradiation may be unacceptable to the patient, especially if it is taken from an area such as the face, and the information must It would thus be of value to establish the amount of cholecalciferol that may be synthesized in skin by a known quantity of U.V. energy.
We have compared the pattern and magnitude of the plasma 25-(OH)D, response both to standardized U.V. irradiation and to oral dosage with cholecalciferol. Cutaneous cholecalciferol synthesis has been calculated as mass of cholecalciferol per millijoule of U.V. energy. The influence of anticonvulsant drugs on the plasma 25-(OH)D, response to U.V. irradiation has also been examined.
Subjects and methods

Subjects
Subjects investigated were white skinned and had no clinical or biochemical features of osteomalacia (Table 1) . Subjects in groups 1-5, who were selected from patients in the Ida Darwin Hospital, Cambridge, rarely went outside. Since there was a considerable variation in weight amongst the subjects, care was taken to match the two groups receiving U.V. irradiation (groups 1 and 2) for weight. The subjects in group 6, who were older than the subjects in groups 1-5, were selected from patients in the Hinchingbrooke Hospital, Huntingdon, and over the period of observation they did not go outside.
Subjects in whom the relationship between plasma concentrations of 25-(OH)D, and cholecalciferol were investigated came from the above groups, from volunteer subjects receiving no therapy, from subjects receiving whole body U.V. irradiation for experimental or therapeutic purposes and from two male subjects taking ergocalciferol (1 -25 mglday) for iatrogenic hypoparathyroidism. Supplementary vitamin D or U.V. irradiation had been administered for at least 9 weeks in all subjects receiving these treatments.
Details of the subjects receiving U.V. energy and cholecalciferol and of the groups into which they were divided appear in Table 1 . Subjects in groups 2-5 had been established on anticonvulsant drugs before the experimental period and continued to receive these drugs during the study.
U.V. irradiation
U.V. irradiation was administered to 600 cmz dorsal skin for 3 midday for 3 dayslweek over a 10 week period in the subjects comprising groups 1 and 2 beginning 30 January 1978. Subjects in group 6 received U.V. irradiation to 900 cmz dorsal skin for 3 midday on 3 dayslweek over 5 weeks in FebruaryIMarch 1979. In all groups the same area of skin was exposed to U.V. irradiation on each occasion.
The U.V. energy source was a Hanovia I A prescription lamp situated 50 cm from the skin surface in groups 1 and 2, and at various distances in group 6. The energy received by each subject in group 6 was known accurately since the power emitted was found to behave in a manner predicted by the inverse square law of irradiation (Dr J. Haybittle, Medical Physics Department, Addenbrooke's Hospital, Hills Road, Cambridge). The power spectrum of this lamp has previously been described [lo] . Since the energy required either to heal rickets or to convert 7-dehydrocholesterol into cholecalciferol (n = 5) (n = 4 ) (+ 1 on primidone) (n = 3) (n = 9) ( n = 7) (n = 3) (+ 1 on primidone) -2.7 f 1.1 3.6 f 2.5 13.3 f 7.5 -1.4 f 0.7 6.5 f 5.8 13.2 f 3.5 900 Nil Nil 10.6 f 6 . 8
is different for each wavelength in the spectrum of this lamp, a factor was calculated from previously published data [l l-131 to express the power of each wavelength as a proportion of the most efficient wavelength. Table 1 , corrected by use of the conversion factor (in vitro).
Oral cholecalciferol intake
The supplementary cholecalciferol used in groups 3-5 was made up in arachis oil and administered in a once-daily dosage.
Vitamin D intake from the diet was assessed by reference to food tables I5 1. [17, 181 . These studies were undertaken in 11 subjects (eight females, three males) who had a mean weight of 54.3 f 0.85 kg and a mean age of 28.0 f 8.4 years. Six subjects were receiving phenobarbitone (1.5 f 0.85 mg/kg) and seven were receiving phenytoin (3.6 f 1.8 mg/kg). Three subjects were receiving both phenobarbitone and phenytoin and one subject was taking primidone. The steady-state equation [17, 181 used in the first method describes the relationship between dosage of a drug and the plasma concentration achieved at plateau level thus:
Cholecalciferol and 25-(0H)D, measurements
Calculation of cholecalciferol synthesis
in which C, = plasma concentration (nmol/l), F = fractional absorption (assumed to be unity), T,,, = half life determined by PHI25-(OH)D3 (days), Vd = volume of distribution (litres) and D = dosage per unit time (nmol/day). The value for the radioactive half life was used because it is less influenced by exogenous sources of vitamin D than is the actual half life, and it is unrelated to the plasma 25-(OH)D, concentration [ 191. The half life determined by the tracer method is also closer to the half life of plasma 25-(OH)D, after very high dosage of vitamin D, when any extraneous vitamin D will make less impact on the rate of decline of plasma 25-(OH)D, from high levels [20] . Moreover the time required for a drug to achieve a concentration of 90% of the plateau level is equivalent to three to four half lives [ 17, 181. The radioactive tracer 25-(OH)D, half life meets this criterion more closely than does the actual half life, which is longer [ 191. The volume of distribution was calculated from Cholecalciferol synthesis in skin may be a single dose of radiolabelled 25-(OH)D,. expressed as cholecalciferol synthesis (nmol/mJ) Although the volume of distribution calculated x energy (mJ/cmz) x area irradiated (cmz). The from the steady-state method is not identical with cholecalciferol intake being the same these two that obtained by the single dose injection, the terms will be equal, and can be rearranged such difference between the two is very small [171. The that daily cholecalciferol synthesis (nmol/mJ) cholecalciferol intake (nmol/kg) x body weight (kg) (1)
Cholecalciferol synthesis in skin was also estimated from the amount of oral cholecalciferol required to sustain a plasma 25-(OH)D, level equivalent to that obtained during U.V. irradiation treatment. Since plasma 25-(OH)D, correlates with cholecalciferol intake per kg body weight (see the Results section), a value of cholecalciferol intake/kg could be found for any plasma 25-(OH)D, level. Assuming that the metabolism of cholecalciferol does not differ according to the origin of cholecalciferol in the body, and ignoring absorptive losses, any concentration of plasma 25-(OH)D, will reflect the same intake of cholecalciferol, be it from the diet or from skin. Thus the relationship of cholecalciferol dosage to plasma 25-(OH)D, concentration allows the total amount of cholecalciferol required to sustain a given 25-(OH)D, level to be calculated from cholecalciferol intake (nmol/kg) x body weight (kg).
Statistics
Regression analysis was performed on a Texas TI-5 1-1 1 1 calculator. Other statistical analyses were performed as described in standard texts, and expressed as mean f S.D.
Ethical approval was obtained for all these experiments from the Ethical committee, Addenbrooke's Hospital, Cambridge. Permission was obtained from all subjects or their guardians.
Results
Details of the subjects receiving U.V. irradiation or oral cholecalciferol appear in Table 1 . The initial plasma 25-(OH)D, concentration was 5.5-16-5 nmol/l, the level being significantly lower in group 2 subjects compared with those in group 1 ( P < 0.05; Mann-Whitney U-test). The intake of cholecalciferol in subjects in groups 1-6 was 2.6 f 0.5 nmol/day with no significant difference between the groups.
Response to U.U. irradiation
Plasma 25-(OH)D, rose in all subjects receiving U.V. irradiation. In groups 1 and 2, plasma 25-(OH)D, levels attained a maximum level after 30-40 days: thereafter the levels remained steady until irradiation was discontinued on day 70 (Fig.  la) . In the subjects comprising group 6, plasma 25-(OH)D, levels at the end of irradiation were 28-0 f 14.4 nmol/l in those receiving 16.7 mJ day-' cm-2, 17.9 f 6.3 nmol/l in those exposed to 8.4 mJ day-' cm-z and 12.9 f 1.0 in those receiving the least U.V. energy. In all the subjects receiving U.V. irradiation the plasma 25-(OH)D, concentration after 5 weeks was related to the daily U.V. energy applied by a power function (Table 2; Fig. 2) . The incremental plasma 25-(OH)D, was linearly related to the daily U.V. energy applied (Table 2; Fig. 3) , the relationship being significant for all subjects. One subject, however, had a disproportionate effect on the slope of the regression and thus the slope relating subjects receiving daily U.V. energy up to 500 mJ day-' kg-I is also shown (Fig. 3) . t U.V. irradiation = mJ/cm'. cm' day-I kg-' (of ml day-' kg-I).
$ Relationship used to determine oral equivalent of cutaneously derived cholecalciferol. $ Regression equation omits two subjects; one initial value was not available and one subject had an exceptionally high degree of
exposure (see the text). This equation describes the relationship up to 500 mJ day-' kg-l.
Plasma 25-(OH)D, levels were followed for 6 weeks after cessation of U.V. irradiation in groups 1 and 2. At the end of the period of irradiation plasma 25-(OH)D, levels were 44.0 f 15.5 nmol/l and 44.3 k 12.3 nmol/l in groups 1 and 2 respectively. Six weeks later the levels were 33.8 f 16.0 nmol/l and 33.5 k 15.3 nmol/l in the two groups.
Oral cholecalciferol dosage
Plasma 25-(OH)D, levels also reached a plateau during oral administration of cholecalciferol (Fig. lb) . Subjects Fig. 4) , the slope of which was similar to that relating U.V. energy and plasma 25-(OH)D, concentration. Table 2 .
Plasma cholecalciferol
Cholecalciferol was present in plasma at a concentration below 5 nmol/l in subjects whose plasma 25-(OH)D, levels were less than 62.5 nmol/l (Fig. 5) . The plasma concentration of cholecalciferol exceeded that of 25-(OH)D, in six subjects (five females, one male), three of whom were receiving U.V. irradiation and three oral cholecalciferol. Cholecalciferol was present at a concentration below 5 nmol/l in subjects from groups 1-3, and was not measured in the subjects in group 6. Plasma cholecalciferol reached a plateau during oral administration of 62.5 nmol of cholecalciferol/day, the mean level being 14.5 f 7.5 nmol/l. In subjects receiving 625 nmol daily (group 5), high levels of cholecalciferol were found in plasma (Table 3) , but, unlike the levels in group 4, plasma cholecalciferol rose rapidly in group 5 subjects and in four (nos. 2, 4, 5, 6; Table 3 ) levels gradually fell even though dosage was continuing. Plasma cholecalciferol fell rapidly when oral supplementation was discontinued.
Radioactive 2.5-(OH)D3 studies
The disappearance of L3H125-(OH)D, fitted a two-compartment system. The slow half life, measured from 48 to 504 h (2-21 days) was 12.9 f 3.6 days, and the total volume of distribution was 11.45 & 3.70 litres or 21.6 & 5.5% of body' weight. The term (21.6/100) x body weight (kg) was used to calculate the value for Vd in the steady-state equation.
Cholecalciferol synthesis in skin
Effective cholecalciferol synthesis in skin was calculated for subjects in group 2 ( Table 4 ). The energy available from the Hanovia lamp was calculated as described and the value of 14.7 mJ/cm* derived from the activity spectrum in vitro (see the Methods section) was used to Davie, unpublished work) . Vitamin D synthesis in human skin (Table 4 ) is similar to that found in rat skin, 0.001 1-0-0027 nmol/mJ being synthesized according to the wavelength used I1 21. A higher value for synthesis calculated from the oral equivalent (Table 4) is expected since not all the cholecalciferol ingested will be absorbed [271. At these rates of synthesis considerable exposure would be required to make any impact on the 2-4 nmol/cm2 of 7-dehydrocholesterol present in skin [31. For the purpose of the calculation, no account was taken of the initial plasma 25-(OH)D, level or of the contribution of dietary vitamin D, since both were low in subjects making up group 2. In subjects from group 1, use of the incremental plasma 25-(OH)D, relationship with U.V. energy (Fig. 3) suggested that cholecalciferol synthesis was 0.001 f 0.0003 nmol/mJ. Dietary vitamin D intake was very low in all subjects, and from the steady-state equation, assuming 75% absorption to calculate the expected steady-state level, it was apparent that no more than 10% of the plateau level could be accounted for from this source.
The potential contribution of U.V. energy to vitamin D status may be assessed by using the data in Table 4 [321 up to 315 nm, the total antirachitic activity was calculated in the same manner as the activity of the Hanovia lamp [ 101, for latitude 45"N. Calculation of the area under the curve relating the wavelength with (energy at 1 x antirachitic activity at d) showed that 17.5 mJ day-' cmP2 are incident in January compared with 712.5 mJ day-' cmP2 in July. However 60% of daily U.V. energy falls in the 4 h around midday G.M.T. 133, 341: thus about 15% of total energy will be available in each hour around midday. Partial cloud cover may reduce energy by 25% and this hour might contain 15 x 75% = 11 -25% of daily U.V. energy. The incident U.V. energy over this 1 h period would thus be 1.97 (17.5 x 0.1125) and 80.2 mJ/cm2 in January and July respectively. However, direct measurement of U.V. energy in June/July in southern England has shown that gardeners were exposed to 21.8 mJ/cm2 per day and indoor workers only to 3.7 mJ/cm2 per day. Expected plateau plasma 25-(OH)D, levels associated with these incident energy values may be calculated either from the relationship in Fig. 2 or by the steady-state equation, with the values for cholecalciferol synthesis depicted in Table 4 . Assuming that the dorsum of the hands and the face are exposed (about 600 cm2) in a 70 kg man, the relationship described in Fig. 2 predicts that daily exposure to 80.2 mJ/cm2 would lead to a plateau level of plasma 25-(OH)D, of 82.7 nmol/l, and that the gardeners and indoor workers would have 26.0 and 10.9 nmol/l respectively. To obtain values from the steady-state equation, a value for D is calculated from the product of area irradiated x energy applied x cholecalciferol synthesis, using the figure of 0.00154 nmol/mJ for cholecalciferol synthesis (Table 4) , and values for T,,, and V, as described above. For the same 70 kg subject with exposure of 600 cm2, exposure to 80.2 mJ/cm2 is associated with a plasma 25-(OH)D, level of 91.0 nmol/l, compared with 24.7 nmol/l for the gardeners and 4.2 nmol/l for indoor workers. Since plasma 25-(OH)D, levels can rise to 72 nmol/l in England [351, it is likely that exposure must be longer or the area irradiated greater than has been accounted for in the above calculation. However, the low plasma 25-(OH)D, levels in groups 1-6 (Table 1) suggest that institutionalized subjects lack both U.V. exposure and vitamin D in the diet, since both are effective at increasing plasma 25-(OH)D, levels (Fig. 1) . The summer months give an opportunity for additional U.V. exposure, especially at weekends, and since the half life of 25-(OH)D, extends over 2 weeks, additional exposure each weekend will have a cumulative effect on plasma 25-(OH)D, concentrations. This will have an effect throughout the year since winter levels of plasma 25-(OH)D, are related to the summer levels [2,361. There is also an advantage in using U.V. irradiation in anticonvulsant-treated subjects. Although doubt exists about the effect of oral vitamin D on the plasma 25-(OH)D, level [25, 371, it is evident from the present study that U.V. exposure yields identical responses in both normal and anticonvulsant-treated subjects.
Note added in proof
Since this paper was submitted, our attention has been drawn to similar conclusions arising out of work in animals [Takada, K. et al. (1981) Journal of Steroid Biochemistry, 14,136 1-1367.
